Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Atherosclerotic Plaque Tissue: Noninvasive Quantitative Assessment of Characteristics with Software-aided Measurements from Conventional CT Angiography.

Sheahan M, Ma X, Paik D, Obuchowski NA, St Pierre S, Newman WP 3rd, Rae G, Perlman ES, Rosol M, Keith JC Jr, Buckler AJ.

Radiology. 2018 Feb;286(2):622-631. doi: 10.1148/radiol.2017170127. Epub 2017 Aug 31.

2.

A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia.

Christaki E, Opal SM, Keith JC Jr, Kessimian N, Palardy JE, Parejo NA, Tan XY, Piche-Nicholas N, Tchistiakova L, Vlasuk GP, Shields KM, Feldman JL, Lavallie ER, Arai M, Mounts W, Pittman DD.

Shock. 2011 May;35(5):492-8. doi: 10.1097/SHK.0b013e31820b2e1c.

PMID:
21263385
3.

Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.

Huang A, Moretto A, Janz K, Lowe M, Bedard PW, Tam S, Di L, Clerin V, Sushkova N, Tchernychev B, Tsao DH, Keith JC, Shaw GD, Schaub RG, Wang Q, Kaila N.

J Med Chem. 2010 Aug 26;53(16):6003-17. doi: 10.1021/jm9013696.

PMID:
20718494
4.

Effect of IL-11 on glomerular expression of TGF-beta and extracellular matrix in nephrotoxic nephritis in Wistar Kyoto rats.

Stangou M, Bhangal G, Lai PC, Smith J, Keith JC Jr, Boyle JJ, Pusey CD, Cook T, Tam FW.

J Nephrol. 2011 Jan-Feb;24(1):106-11.

PMID:
20640990
5.

Estrogen receptor beta agonism increases survival in experimentally induced sepsis and ameliorates the genomic sepsis signature: a pharmacogenomic study.

Christaki E, Opal SM, Keith JC Jr, Kessinian N, Palardy JE, Parejo NA, Lavallie E, Racie L, Mounts W, Malamas MS, Mewshaw RE, Harris HA, Vlasuk GP.

J Infect Dis. 2010 Apr 15;201(8):1250-7. doi: 10.1086/651276.

PMID:
20205571
6.

LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse.

Quinet EM, Basso MD, Halpern AR, Yates DW, Steffan RJ, Clerin V, Resmini C, Keith JC, Berrodin TJ, Feingold I, Zhong W, Hartman HB, Evans MJ, Gardell SJ, DiBlasio-Smith E, Mounts WM, LaVallie ER, Wrobel J, Nambi P, Vlasuk GP.

J Lipid Res. 2009 Dec;50(12):2358-70. doi: 10.1194/jlr.M900037-JLR200. Epub 2009 Mar 24.

7.

Assessment of arterial stiffness, a translational medicine biomarker system for evaluation of vascular risk.

Wang X, Keith JC Jr, Struthers AD, Feuerstein GZ.

Cardiovasc Ther. 2008 Fall;26(3):214-23. doi: 10.1111/j.1755-5922.2008.00051.x. Review.

PMID:
18786091
8.

Dose-dependent effects of recombinant human interleukin-11 on the systemic hemodynamic function and urination.

Honma K, Koles NL, Alam HB, Keith JC Jr, Pollack M.

Kurume Med J. 2007;54(3-4):73-6.

9.

Expression of the cysteine protease legumain in vascular lesions and functional implications in atherogenesis.

Clerin V, Shih HH, Deng N, Hebert G, Resmini C, Shields KM, Feldman JL, Winkler A, Albert L, Maganti V, Wong A, Paulsen JE, Keith JC Jr, Vlasuk GP, Pittman DD.

Atherosclerosis. 2008 Nov;201(1):53-66. doi: 10.1016/j.atherosclerosis.2008.01.016. Epub 2008 Feb 21.

PMID:
18377911
10.

Utility of animal models for identification of potential therapeutics for rheumatoid arthritis.

Hegen M, Keith JC Jr, Collins M, Nickerson-Nutter CL.

Ann Rheum Dis. 2008 Nov;67(11):1505-15. Epub 2007 Nov 29. Review.

PMID:
18055474
11.

Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection.

Lutterloh EC, Opal SM, Pittman DD, Keith JC Jr, Tan XY, Clancy BM, Palmer H, Milarski K, Sun Y, Palardy JE, Parejo NA, Kessimian N.

Crit Care. 2007;11(6):R122.

12.

Interleukin-11.

Dorner AJ, Goldman SJ, Keith JC Jr.

BioDrugs. 1997 Dec;8(6):418-29.

PMID:
18031104
13.

Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis.

Bedard PW, Clerin V, Sushkova N, Tchernychev B, Antrilli T, Resmini C, Keith JC Jr, Hennan JK, Kaila N, Debernardo S, Janz K, Wang Q, Crandall DL, Schaub RG, Shaw GD, Carter LL.

J Pharmacol Exp Ther. 2008 Feb;324(2):497-506. Epub 2007 Nov 16.

PMID:
18024786
14.

Estrogen receptor dependent inhibitors of NF-kappaB transcriptional activation-1 synthesis and biological evaluation of substituted 2-cyanopropanoic acid derivatives: pathway selective inhibitors of NF-kappaB, a potential treatment for rheumatoid arthritis.

Caggiano TJ, Brazzale A, Ho DM, Kraml CM, Trybulski E, Chadwick CC, Chippari S, Borges-Marcucci L, Eckert A, Keith JC, Kenney T, Harnish DC.

J Med Chem. 2007 Nov 1;50(22):5245-8. Epub 2007 Sep 29.

PMID:
17902637
15.

TelEmergency: a novel system for delivering emergency care to rural hospitals.

Galli R, Keith JC, McKenzie K, Hall GS, Henderson K.

Ann Emerg Med. 2008 Mar;51(3):275-84. Epub 2007 Aug 30.

PMID:
17764784
16.

Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.

Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, Senices M, Wu PW, Sibley B, Leathurby Y, Brown TP, Nickerson-Nutter C, Keith JC Jr, Collins M.

Arthritis Rheum. 2007 Apr;56(4):1152-63.

17.

2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic acid (PSI-697): identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists.

Kaila N, Janz K, Huang A, Moretto A, DeBernardo S, Bedard PW, Tam S, Clerin V, Keith JC Jr, Tsao DH, Sushkova N, Shaw GD, Camphausen RT, Schaub RG, Wang Q.

J Med Chem. 2007 Jan 11;50(1):40-64.

PMID:
17201409
18.

Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.

Kaila N, Janz K, DeBernardo S, Bedard PW, Camphausen RT, Tam S, Tsao DH, Keith JC Jr, Nickerson-Nutter C, Shilling A, Young-Sciame R, Wang Q.

J Med Chem. 2007 Jan 11;50(1):21-39.

PMID:
17201408
19.

WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock.

Cristofaro PA, Opal SM, Palardy JE, Parejo NA, Jhung J, Keith JC Jr, Harris HA.

Crit Care Med. 2006 Aug;34(8):2188-93.

PMID:
16755255
20.

Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs.

Hennan JK, Swillo RE, Morgan GA, Keith JC Jr, Schaub RG, Smith RP, Feldman HS, Haugan K, Kantrowitz J, Wang PJ, Abu-Qare A, Butera J, Larsen BD, Crandall DL.

J Pharmacol Exp Ther. 2006 Apr;317(1):236-43. Epub 2005 Dec 12.

PMID:
16344331
21.

The activity of pathway-selective estrogen receptor ligands in experimental septic shock.

Opal SM, Palardy JE, Cristofaro P, Parejo N, Jhung JW, Keith JC Jr, Chippari S, Caggiano TJ, Steffan RJ, Chadwick CC, Harnish DC.

Shock. 2005 Dec;24(6):535-40.

PMID:
16317384
22.

Organ messenger ribonucleic acid and plasma proteome changes in the adjuvant-induced arthritis model: responses to disease induction and therapy with the estrogen receptor-beta selective agonist ERB-041.

Follettie MT, Pinard M, Keith JC Jr, Wang L, Chelsky D, Hayward C, Kearney P, Thibault P, Paramithiotis E, Dorner AJ, Harris HA.

Endocrinology. 2006 Feb;147(2):714-23. Epub 2005 Nov 3.

PMID:
16269464
23.

Interleukin-11 reduces renal injury and glomerular NF-kappa B activity in murine experimental glomerulonephritis.

Lai PC, Smith J, Bhangal G, Chaudhry KA, Chaudhry AN, Keith JC Jr, Tam FW, Pusey CD, Cook HT.

Nephron Exp Nephrol. 2005;101(4):e146-54. Epub 2005 Aug 30.

PMID:
16131809
24.

A monoclonal antibody against kininogen reduces inflammation in the HLA-B27 transgenic rat.

Keith JC Jr, Sainz IM, Isordia-Salas I, Pixley RA, Leathurby Y, Albert LM, Colman RW.

Arthritis Res Ther. 2005;7(4):R769-76. Epub 2005 Apr 4.

25.

Quinic acid derivatives as sialyl Lewis(x)-mimicking selectin inhibitors: design, synthesis, and crystal structure in complex with E-selectin.

Kaila N, Somers WS, Thomas BE, Thakker P, Janz K, DeBernardo S, Tam S, Moore WJ, Yang R, Wrona W, Bedard PW, Crommie D, Keith JC Jr, Tsao DH, Alvarez JC, Ni H, Marchese E, Patton JT, Magnani JL, Camphausen RT.

J Med Chem. 2005 Jun 30;48(13):4346-57.

PMID:
15974587
26.

ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.

Mewshaw RE, Edsall RJ Jr, Yang C, Manas ES, Xu ZB, Henderson RA, Keith JC Jr, Harris HA.

J Med Chem. 2005 Jun 16;48(12):3953-79.

PMID:
15943471
27.

The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappa B transcriptional activity in models of rheumatoid arthritis.

Keith JC Jr, Albert LM, Leathurby Y, Follettie M, Wang L, Borges-Marcucci L, Chadwick CC, Steffan RJ, Harnish DC.

Arthritis Res Ther. 2005;7(3):R427-38. Epub 2005 Feb 21.

28.
29.

Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity.

Chadwick CC, Chippari S, Matelan E, Borges-Marcucci L, Eckert AM, Keith JC Jr, Albert LM, Leathurby Y, Harris HA, Bhat RA, Ashwell M, Trybulski E, Winneker RC, Adelman SJ, Steffan RJ, Harnish DC.

Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2543-8. Epub 2005 Feb 7.

30.

Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis.

Steffan RJ, Matelan E, Ashwell MA, Moore WJ, Solvibile WR, Trybulski E, Chadwick CC, Chippari S, Kenney T, Eckert A, Borges-Marcucci L, Keith JC, Xu Z, Mosyak L, Harnish DC.

J Med Chem. 2004 Dec 16;47(26):6435-8.

PMID:
15588074
31.

Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme.

Zhang Y, Hegen M, Xu J, Keith JC Jr, Jin G, Du X, Cummons T, Sheppard BJ, Sun L, Zhu Y, Rao VR, Wang Q, Xu W, Cowling R, Nickerson-Nutter CL, Gibbons J, Skotnicki J, Lin LL, Levin J.

Int Immunopharmacol. 2004 Dec 20;4(14):1845-57.

PMID:
15531300
32.

Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.

Malamas MS, Manas ES, McDevitt RE, Gunawan I, Xu ZB, Collini MD, Miller CP, Dinh T, Henderson RA, Keith JC Jr, Harris HA.

J Med Chem. 2004 Oct 7;47(21):5021-40.

PMID:
15456246
33.

Oral treatment with recombinant human interleukin-11 improves mucosal transport in the colon of human leukocyte antigen-B27 transgenic rats.

Venkova K, Keith JC Jr, Greenwood-Van Meerveld B.

J Pharmacol Exp Ther. 2004 Jan;308(1):206-13. Epub 2003 Oct 20.

PMID:
14569059
34.

Evaluation of an estrogen receptor-beta agonist in animal models of human disease.

Harris HA, Albert LM, Leathurby Y, Malamas MS, Mewshaw RE, Miller CP, Kharode YP, Marzolf J, Komm BS, Winneker RC, Frail DE, Henderson RA, Zhu Y, Keith JC Jr.

Endocrinology. 2003 Oct;144(10):4241-9. Erratum in: Endocrinology. 2006 May;147(5):2085.

PMID:
14500559
35.

Beneficial effects of estrogen treatment in the HLA-B27 transgenic rat model of inflammatory bowel disease.

Harnish DC, Albert LM, Leathurby Y, Eckert AM, Ciarletta A, Kasaian M, Keith JC Jr.

Am J Physiol Gastrointest Liver Physiol. 2004 Jan;286(1):G118-25. Epub 2003 Sep 4.

36.

Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs.

Russell KE, Olsen EH, Raymer RA, Merricks EP, Bellinger DA, Read MS, Rup BJ, Keith JC Jr, McCarthy KP, Schaub RG, Nichols TC.

Blood. 2003 Dec 15;102(13):4393-8. Epub 2003 Aug 21.

PMID:
12933577
37.

Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP).

Olsen EH, McCain AS, Merricks EP, Fischer TH, Dillon IM, Raymer RA, Bellinger DA, Fahs SA, Montgomery RR, Keith JC Jr, Schaub RG, Nichols TC.

Blood. 2003 Jul 15;102(2):436-41. Epub 2003 Mar 20.

PMID:
12649145
38.

IL-11-induced reduction of C/EBP transcription factor binding may contribute to the IL-12 downregulation in tumor-bearing mice.

Torroella-Kouri M, Keith JC, Ivanova M, Lopez DM.

Int J Oncol. 2003 Feb;22(2):439-48.

PMID:
12527946
39.

Orally administered recombinant human interleukin-11 is protective in experimental neutropenic sepsis.

Opal SM, Keith JC Jr, Jhung J, Palardy JE, Parejo N, Marchese E, Maganti V.

J Infect Dis. 2003 Jan 1;187(1):70-6. Epub 2002 Dec 13.

PMID:
12508148
40.

Placental syncytin expression in normal and preeclamptic pregnancies.

Keith JC Jr, Pijnenborg R, Van Assche FA.

Am J Obstet Gynecol. 2002 Oct;187(4):1122-3; author reply 1123-4. No abstract available.

PMID:
12389018
41.

Differential effects of IL-11 on rat blastocysts and decidua during the peri-implantation period.

Caluwaerts S, Pijnenborg R, Luyten C, Keith JC Jr, Van Assche FA.

Am J Reprod Immunol. 2002 Apr;47(4):231-41.

PMID:
12069390
42.

Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys.

McCarthy K, Stewart P, Sigman J, Read M, Keith JC Jr, Brinkhous KM, Nichols TC, Schaub RG.

Thromb Haemost. 2002 May;87(5):824-30.

PMID:
12038784
43.

Downregulation of placental syncytin expression and abnormal protein localization in pre-eclampsia.

Lee X, Keith JC Jr, Stumm N, Moutsatsos I, McCoy JM, Crum CP, Genest D, Chin D, Ehrenfels C, Pijnenborg R, van Assche FA, Mi S.

Placenta. 2001 Nov;22(10):808-12.

PMID:
11718567
44.

Interleukin-11 attenuates nephrotoxic nephritis in Wistar Kyoto rats.

Lai PC, Cook HT, Smith J, Keith JC Jr, Pusey CD, Tam FW.

J Am Soc Nephrol. 2001 Nov;12(11):2310-20.

45.
46.

Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs.

Russell KE, Read MS, Bellinger DA, Leitermann K, Rup BJ, McCarthy KP, Keith JC Jr, Khor SP, Schaub RG, Nichols TC.

Thromb Haemost. 2001 Mar;85(3):445-9.

PMID:
11307812
47.
48.

Effect of recombinant human interleukin-11 on motilin and substance P release in normal and inflamed rabbits.

Depoortere I, Thijs T, Thielemans L, Keith JC, Van Assche G, Peeters TL.

Regul Pept. 2001 Mar 2;97(2-3):111-9.

PMID:
11164946
49.

Recombinant human interleukin-11 decreases severity of acute necrotizing pancreatitis in mice.

Shimizu T, Shiratori K, Sawada T, Kobayashi M, Hayashi N, Saotome H, Keith JC.

Pancreas. 2000 Aug;21(2):134-40.

PMID:
10975706
50.

Recombinant human interleukin-11 modulates ion transport and mucosal inflammation in the small intestine and colon.

Greenwood-Van Meerveld B, Tyler K, Keith JC Jr.

Lab Invest. 2000 Aug;80(8):1269-80.

PMID:
10950118

Supplemental Content

Loading ...
Support Center